

## PRODUCT INFORMATION

|   |  |
|---|--|
| <b>Clone ID</b>                         | DMC466   |
| <b>Target</b>                           | CSPG4  |
| <b>Synonyms</b>                         | CSPG4A; HMW-MAA; MCSP; MCSPG; MEL-CSPG; MSK16; NG2   |
| <b>Host Species</b>                     | Rabbit   |
| <b>Description</b>                      | Biotinylated Anti-CSPG4 antibody(DMC466); IgG1 Chimeric mAb  |
| <b>Delivery</b>                         | 2-3 weeks  |
| <b>Uniprot ID</b>                       | Q6UVK1   |
| <b>IgG type</b>                         | Rabbit/Human Fc chimeric IgG1  |
| <b>Clonality</b>                        | Monoclonal   |
| <b>Reactivity</b>                       | Human  |
| <b>Applications</b>                     | Flow Cyt   |
| <b>Recommended Dilutions</b>            | Flow Cyt 1:100   |
| <b>Purification</b>                     | Purified from cell culture supernatant by affinity chromatography  |
| <b>Formulation &amp; Reconstitution</b> | Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.   |
| <b>Storage &amp; Shipping</b>           | Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.  |
| <b>Background</b>                       | A human melanoma-associated chondroitin sulfate proteoglycan plays a role in stabilizing cell-substratum interactions during early events of melanoma cell spreading on endothelial basement membranes. CSPG4 represents an integral membrane chondroitin sulfate proteoglycan expressed by human malignant melanoma cells. [provided by RefSeq; Jul 2008] |
| <b>Usage</b>                            | Research use only  |
| <b>Conjugate</b>                        | Biotinylated   |
| <b>DIMA Disclaimer</b>                  | All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement.   |

